2024
CASE STUDY
BIOTECHNOLOGY
Trusted by:
... and many others
THE GOAL
CUSTOMER'S Profile
Launch the program. As a new brand, Ambros needed to build credibility through a consistent brand identity across all assets. Ambros' ultimate goal is to streamline its fundraising and licensing efforts.
Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicine against complex regional pain syndrome type 1 (CRPS-1), a devastating rare metabolic bone disease that causes severe pain following trauma to the bone or an injury.
Brand Identity Complex:
THE DELIVERABLES
5
meetings
Communication with client is essential for us. To listen to them and provide with the best result
4
rounds
Four feedback rounds on the production stage
Claryfiying objectives, requirements, and references
Final Website Version
Final Pitch Deck Design
Final Logo and Brand Design
8
weeks
Duration from the first kick-off meeting to the final delivery of all the materials
Providing final pitch deck
Presentation of the pitch deck, implementation of changes according to revisions
First draft of the MoA video
WEEK 1
WEEK 3
WEEK 6
WEEK 7
WEEK 8
The Ambros Therapeutics logo embodies strength, dynamism, and innovation. Its key element is the wave ‒ a symbol of power, energy, and continuous progress.
We carefully chose the favicon, the wave itself, the typography and the color scheme, so that Ambros would be able to include the logo everywhere: from the office to the website.
Ambros's technology is highly innovative and cannot be conveyed in words alone.
Therefore, we transformed this intricate concept into clear, engaging visuals that both served fundraising purposes and an explanatory role during the clinical trials.
We developed Ambros's website from scratch.
After finalizing the logo and general brand identity (color palette, templates, fonts), we developed the website. The website consists of 8 pages and took 3 weeks to complete.
On Decemer 16th 2025,
"Ambros Therapeutics launched publicly with a $125 million Series A financing co-led by RA Capital Management and Patient Square Capital‘s strategic health care investment arm Enavate Sciences. The company licensed the rights to neridronate, which is used to treat Complex Regional Pain Syndrome."
Source: Crunchbase
Danielle Spangler
Ambros Therapeutics
Thanks to the newly developed comms assets, BiPER Therapeutics received the Boston Biotech Summit's Vice Champion Award and was nominated for the Best Startup category by The Galien Foundation.
I personally wanted to thank you for all your hard work and kindness. You were so patient and professional. I want to sincerely thank you and your team for the work you delivered. The website, brand, and visual assets have served us well, and we've appreciated the partnership.
EU & US based,
operating globally since 2016
4.9/5
customer satisfaction
2010 first scientific videos were developed
15
years of expertise in scientific communications
500+
successful projects
1000+
minutes of scientific video
20 +
highly skilled professionals, 3 PhD level colleagues
100+
pitch decks and sales aids
Our mission:
to help bring 100 Impactful products/ideas to market by 2030 (5 years!).
Clients
and many more....
Winning Hearts and Minds.
Let's talk!
Andrii Koniukh
Co-Founder and CEO
EU •
Yurii Svidinenko
Co-Founder and Production director
US •